Entities / Company
Capricor Therapeutics (United States).
company in Beverly Hills, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 30
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
TipRanks provided KPI data for investment decisions concerning Hoth Therapeutics on June 25, 2025.Speculative2 reports
-
Capricor Therapeutics is seeking regulatory approval from the FDA for therapeutics targeting Duchenne Muscular Dystrophy.Some support3 reports4 developments inside
-
The FDA informed Capricor Therapeutics that regulatory review is not required for its drug.Speculative1 report
-
The FDA announced its decision regarding the Advisory Committee for Capricor Therapeutics' drug, deramiocel, on June 26, 2025.Some support2 reports
-
Capricor Therapeutics is developing therapeutics for Duchenne muscular dystrophy and had a Type A meeting scheduled with the FDA.Some support3 reports
-
A Discounted Cash Flow (DCF) model was used on August 13, 2025, to estimate the intrinsic value of Capricor Therapeutics.Some support1 report
-
FDA cleared the IND application for a clinical trial of the StealthX™ vaccine, funded by NIAID and conducted in collaboration with NIH and HHS.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Capricor Therapeutics (United States) this week
News at the entities that move Capricor Therapeutics (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Capricor Therapeutics (United States)
-
National Institutes of Health OperationalPDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.Moves Capricor Therapeutics (United States)
Connections
The 3 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
FDA formally regulates Capricor Therapeutics, reviewing its product applications and manufacturing capabilities.
-
DMD Operational
Capricor Therapeutics is actively developing and seeking approval for therapies targeting Duchenne Muscular Dystrophy.
-
National Institutes of Health Operational
Capricor Therapeutics collaborates with the National Institutes of Health on research and clinical trials.
History
Events by the month they beganJune 2026
8 events- Capricor Therapeutics is seeking FDA approval for its deramiocel cell therapy, with announcements made at biotech events and trading on the electronic stock exchange.
- TipRanks provided KPI data for investment decisions concerning Hoth Therapeutics on June 25, 2025.
- Capricor Therapeutics is seeking regulatory approval from the FDA for therapeutics targeting Duchenne Muscular Dystrophy.
- The FDA informed Capricor Therapeutics that regulatory review is not required for its drug.
- The FDA announced its decision regarding the Advisory Committee for Capricor Therapeutics' drug, deramiocel, on June 26, 2025.
- Capricor Therapeutics is developing therapeutics for Duchenne muscular dystrophy and had a Type A meeting scheduled with the FDA.
- A Discounted Cash Flow (DCF) model was used on August 13, 2025, to estimate the intrinsic value of Capricor Therapeutics.
- FDA cleared the IND application for a clinical trial of the StealthX™ vaccine, funded by NIAID and conducted in collaboration with NIH and HHS.